Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
14 mars 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
25 févr. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant...
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
13 févr. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show...
Summit Therapeutics to Present at the BIO CEO & Investor Conference
08 févr. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Present at the BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 8 February 2019 – Summit Therapeutics...
Holding(s) in Company
15 janv. 2019 12h45 HE
|
Summit Therapeutics plc
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...
Award of Restricted Stock Units
14 janv. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Award of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 14 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a...
Holding(s) in Company
10 janv. 2019 11h15 HE
|
Summit Therapeutics plc
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...
Completion of $25 million subscription
10 janv. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Completion of $25 million subscription Oxford, UK, and Cambridge, MA, US, 10 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ:...
Holding(s) in Company
10 janv. 2019 06h30 HE
|
Summit Therapeutics plc
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...
Completion of $25 million Subscription
10 janv. 2019 02h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Completion of $25 million subscription Oxford, UK, and Cambridge, MA, US, 10 January 2019 - Summit Therapeutics (AIM: SUMM,...